QR kód

Personalized sirolimus regimen for vascular malformations: a retrospective analysis of VASE cohort

Abstract Background The mTOR inhibitor Sirolimus was shown to improve symptoms in patients with slow-flow vascular malformations, but long-term continuous use is limited by cumulative toxicity. A personalized approach with intermittent regimens may offer similar efficacy with fewer adverse effects (...

Celý popis

Uloženo v:
Hlavní autoři: Emmanuel Seront, An Van Damme, Julien Coulie, Miikka Vikkula, Laurence M. Boon
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2025-12-01
Edice:Orphanet Journal of Rare Diseases
Témata:
Slow-flow vascular malformation
Sirolimus
Intermittent
On-demand
Personalized regimen
Adverse events
On-line přístup:https://doi.org/10.1186/s13023-025-04151-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky